Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Oxygen is a master regulator of the immunogenicity of primary human glioma cells.

Olin MR, Andersen BM, Litterman AJ, Grogan PT, Sarver AL, Robertson PT, Liang X, Chen W, Parney IF, Hunt MA, Blazar BR, Ohlfest JR.

Cancer Res. 2011 Nov 1;71(21):6583-9. doi: 10.1158/0008-5472.CAN-11-1166. Epub 2011 Sep 9.

2.

Generation of dendritic cell-tumor cell hybrids by electrofusion for clinical vaccine application.

Trevor KT, Cover C, Ruiz YW, Akporiaye ET, Hersh EM, Landais D, Taylor RR, King AD, Walters RE.

Cancer Immunol Immunother. 2004 Aug;53(8):705-14. Epub 2004 Mar 26.

PMID:
15048588
3.
4.

Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens.

Xu Q, Liu G, Yuan X, Xu M, Wang H, Ji J, Konda B, Black KL, Yu JS.

Stem Cells. 2009 Aug;27(8):1734-40. doi: 10.1002/stem.102.

5.

EphA2 as a glioma-associated antigen: a novel target for glioma vaccines.

Hatano M, Eguchi J, Tatsumi T, Kuwashima N, Dusak JE, Kinch MS, Pollack IF, Hamilton RL, Storkus WJ, Okada H.

Neoplasia. 2005 Aug;7(8):717-22.

6.

Cytotoxic T cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells.

Ebstein F, Sapede C, Royer PJ, Marcq M, Ligeza-Poisson C, Barbieux I, Cellerin L, Dabouis G, Grégoire M.

Am J Respir Crit Care Med. 2004 Jun 15;169(12):1322-30. Epub 2004 Apr 7.

PMID:
15070823
7.

Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells.

Schmidt SM, Schag K, Müller MR, Weck MM, Appel S, Kanz L, Grünebach F, Brossart P.

Blood. 2003 Jul 15;102(2):571-6. Epub 2003 Feb 6.

8.

Superior efficacy of tumor cell vaccines grown in physiologic oxygen.

Olin MR, Andersen BM, Zellmer DM, Grogan PT, Popescu FE, Xiong Z, Forster CL, Seiler C, SantaCruz KS, Chen W, Blazar BR, Ohlfest JR.

Clin Cancer Res. 2010 Oct 1;16(19):4800-8. doi: 10.1158/1078-0432.CCR-10-1572. Epub 2010 Sep 21.

9.

In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.

Wu A, Oh S, Gharagozlou S, Vedi RN, Ericson K, Low WC, Chen W, Ohlfest JR.

J Immunother. 2007 Nov-Dec;30(8):789-97.

PMID:
18049330
10.
11.

Induction of cytotoxic T lymphocytes against human cancer cell lines using dendritic cell-tumor cell hybrids generated by a newly developed electrofusion technique.

Imura K, Ueda Y, Hayashi T, Itoh T, Shimizu K, Tamai H, Yano Y, Naito K, Kohara J, Nakane K, Matsuura Y, Takeda A, Takeda T, Kawai K, Yamagishi H.

Int J Oncol. 2006 Sep;29(3):531-9.

PMID:
16865268
12.

Identification of novel human leukocyte antigen-A*0201-restricted, cytotoxic T lymphocyte epitopes on CD133 for cancer stem cell immunotherapy.

Ji J, Judkowski VA, Liu G, Wang H, Bunying A, Li Z, Xu M, Bender J, Pinilla C, Yu JS.

Stem Cells Transl Med. 2014 Mar;3(3):356-64. doi: 10.5966/sctm.2013-0135. Epub 2013 Dec 27.

13.

Efficient induction of a Her2-specific anti-tumor response by dendritic cells pulsed with a Hsp70L1-Her2(341-456) fusion protein.

Fu Q, Wu Y, Yan F, Wang N, Wang W, Cao X, Wang Y, Wan T.

Cell Mol Immunol. 2011 Sep;8(5):424-32. doi: 10.1038/cmi.2011.21. Epub 2011 Jul 25.

14.
15.

Improvement of dendritic-based vaccine efficacy against hepatitis B virus-related hepatocellular carcinoma by two tumor-associated antigen gene-infected dendritic cells.

Yang JY, Cao DY, Xue Y, Yu ZC, Liu WC.

Hum Immunol. 2010 Mar;71(3):255-62. doi: 10.1016/j.humimm.2009.12.010. Epub 2010 Jan 8.

PMID:
20036295
16.

Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.

Tso CL, Zisman A, Pantuck A, Calilliw R, Hernandez JM, Paik S, Nguyen D, Gitlitz B, Shintaku PI, de Kernion J, Figlin R, Belldegrun A.

Cancer Res. 2001 Nov 1;61(21):7925-33.

17.

HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells.

Liu G, Ying H, Zeng G, Wheeler CJ, Black KL, Yu JS.

Cancer Res. 2004 Jul 15;64(14):4980-6.

18.

Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.

André F, Chaput N, Schartz NE, Flament C, Aubert N, Bernard J, Lemonnier F, Raposo G, Escudier B, Hsu DH, Tursz T, Amigorena S, Angevin E, Zitvogel L.

J Immunol. 2004 Feb 15;172(4):2126-36.

19.

Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma.

Yamanaka R, Honma J, Tsuchiya N, Yajima N, Kobayashi T, Tanaka R.

J Neurooncol. 2005 Apr;72(2):107-13.

PMID:
15925989
20.

Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain.

Okano F, Storkus WJ, Chambers WH, Pollack IF, Okada H.

Clin Cancer Res. 2002 Sep;8(9):2851-5. Erratum in: Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3552.

Items per page

Supplemental Content

Write to the Help Desk